Skip to main content
. 2019 Aug 7;18(4):3873–3879. doi: 10.3892/ol.2019.10729

Table II.

pCR correlation with neoadjuvant treatment.

Chemotherapy regimen Patient number pCR number pCR rate (%)
EC → TXT 5 0 0
EC → TXT + H 2 0 0
TMC 16 1 6
TEC + H 11 2 18
TEC 60 17 28
TMC + H 6 2 33
PERT/H/TXT 17 13 76

EC, Epirubicin + Cyclophosphamide; TXT, Taxotere; H, Herceptin (Trastuzumab); TMC, Docetaxel + Myocet (liposomal doxorubicin) + Cyclophosphamide; TEC, Docetaxel + Epirubicin + Cyclophosphamide; PERT, Pertuzumab.